Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
58
GNGBF Quote, Financials, Valuation and Earnings
Last price:
$22.10
Seasonality move
:
8.24%
Day range:
$22.10 - $22.10
52-week range:
$15.62 - $22.10
Dividend yield:
2.19%
P/E ratio:
29.60x
P/S ratio:
1.71x
P/B ratio:
1.94x
Volume:
--
Avg. volume:
19
1-year change:
40.94%
Market cap:
$6B
Revenue:
$3.3B
EPS (TTM):
$0.75
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Getinge AB has -- downside to fair value with a price target of -- per share.
GNGBF vs. S&P 500
-
Over the past 5 trading days, Getinge AB has underperformed the S&P 500 by -1.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Getinge AB does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Getinge AB has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Getinge AB reported revenues of $864.3M.
Earnings Growth
-
Getinge AB has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Getinge AB reported earnings per share of $0.22.
Enterprise value:
7B
EV / Invested capital:
1.60x
Price / LTM sales:
1.71x
EV / EBIT:
15.20x
EV / Revenue:
1.97x
PEG ratio (5yr expected):
1.08x
EV / Free cash flow:
22.89x
Price / Operating cash flow:
19.81x
Enterprise value / EBITDA:
10.34x
Gross Profit (TTM):
$1.5B
Return On Assets:
3.45%
Net Income Margin (TTM):
5.83%
Return On Equity:
6.74%
Return On Invested Capital:
4.94%
Operating Margin:
12.18%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.9B | $3.2B | $3.5B | $755.1M | $864.3M | |
| Gross Profit | $1.2B | $1.4B | $1.5B | $314.4M | $371.3M | |
| Operating Income | $330.3M | $351.5M | $457.3M | $74.6M | $105.3M | |
| EBITDA | $533.1M | $548.1M | $672.6M | $124.6M | $159.4M | |
| Diluted EPS | $0.77 | $0.59 | $0.75 | $0.00 | $0.22 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.7B | $1.6B | $1.8B | $1.6B | $1.8B | |
| Total Assets | $5B | $4.7B | $4.9B | $5.9B | $6B | |
| Current Liabilities | $319.1M | $209.1M | $1.1B | $1.5B | $1.3B | |
| Total Liabilities | $2.2B | $1.9B | $2B | $2.9B | $2.9B | |
| Total Equity | $2.7B | $2.8B | $2.9B | $3B | $3.1B | |
| Total Debt | $635M | $457.7M | $454.4M | $754.9M | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $246.4M | $366.5M | $432.7M | $65.2M | $115.8M | |
| Cash From Investing | -$160.2M | -$875.5M | -$299M | -$298.5M | -$34.1M | |
| Cash From Financing | -$44.1M | $215.2M | -$66.1M | $226.2M | $19.8M | |
| Free Cash Flow | $120.9M | $243.6M | $303.8M | $34.1M | $83.7M | |
GNGBF
Sector
Market Cap
$6B
$28M
Price % of 52-Week High
100%
51.03%
Dividend Yield
2.19%
0%
Shareholder Yield
0.9%
-1.54%
1-Year Price Total Return
40.95%
-17.48%
Beta (5-Year)
0.728
0.518
Dividend yield:
2.19%
Annualized payout:
$0.40
Payout ratio:
-86.3%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$21.96
200-day SMA
Buy
Level
$21.00
Bollinger Bands (100)
Buy
Level
20.8 - 21.36
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$21.39
Relative Strength Index (RSI14)
Buy
Level
99.97
ADX Line
Buy
Level
99.98
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$21.15
MACD (12, 26)
Buy
Level
0.30
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
738
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.1177)
Buy
CA Score
(Annual)
Level (0.1723)
Buy
Beneish M-Score
(Annual)
Level (-2.6725)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-0.1745)
Buy
Piotroski F Score
(Annual)
Level (6)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Getinge AB is a medical technology company specializes in providing equipment, systems, operating rooms, intensive-care units to the healthcare and the life science industries. It offers products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. The firm operates through the following segments: Acute Care Therapies, Life Science and Surgical Workflows. The Acute Care Therapies segment offers solutions for life support in acute health conditions. The Life Science segment offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in biopharmaceutical production, biomedical research, medical device manufacturing and laboratory applications. The Surgical Workflows segment offers products and services for efficient disinfection and sterilization of instruments used in operations, operating tables and other high-quality hardware for operating rooms and advanced IT systems for efficient and secure hospital workflows. The company was founded by Olander Larsson in 1904 and is headquartered in Gothenburg, Sweden.
Stock Forecast FAQ
In the current month, GNGBF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GNGBF average analyst price target in the past 3 months is --.
-
Where Will Getinge AB Stock Be In 1 Year?
According to analysts, the consensus estimate is that Getinge AB share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Getinge AB?
Analysts are divided on their view about Getinge AB share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Getinge AB is a Sell and believe this share price will rise from its current level to --.
-
What Is Getinge AB's Price Target?
The price target for Getinge AB over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GNGBF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Getinge AB is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of GNGBF?
You can purchase shares of Getinge AB via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Getinge AB shares.
-
What Is The Getinge AB Share Price Today?
Getinge AB was last trading at $22.10 per share. This represents the most recent stock quote for Getinge AB. Yesterday, Getinge AB closed at $22.10 per share.
-
How To Buy Getinge AB Stock Online?
In order to purchase Getinge AB stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GNGBF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GNGBF
Sector
P/E ratio
29.60x
23.89x
PEG ratio
1.08x
-0.01x
P/B ratio
1.94x
1.82x
Price / LTM sales
1.71x
1.60x
Growth Metrics
GNGBF
Sector
Revenue growth
14.46%
4.62%
Earnings growth
31085.71%
10.88%
Revenue (5-year growth)
3.21%
6.5%
Earnings forecast
--
-$0.21
Profitability
GNGBF
Sector
Profitability FY 2024
$1.4B
$3.5M
Return on invested capital
4.94%
-31.77%
Return on assets
3.45%
-27.96%
Return on equity
6.74%
-37.63%
Earnings Date
Last Earnings Date
Oct
21
Next Earnings Date
Jan
27
Estimated Next Earnings Date
Jan
20
Balance Sheet
GNGBF
Sector
Total cash
$302.7M
$26.3M
Short term investments
--
$25.7M
Total assets
$6B
$78M
Long term debt
$1.1B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
